Cargando…

Development and dosimetry of (203)Pb/(212)Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?

PURPOSE: The aims of this study were to develop a prostate-specific membrane antigen (PSMA) ligand for labelling with different radioisotopes of lead and to obtain an approximation of the dosimetry of a simulated (212)Pb-based alpha therapy using its (203)Pb imaging analogue. METHODS: Four novel Glu...

Descripción completa

Detalles Bibliográficos
Autores principales:	dos Santos, José Carlos, Schäfer, Martin, Bauder-Wüst, Ulrike, Lehnert, Wencke, Leotta, Karin, Morgenstern, Alfred, Kopka, Klaus, Haberkorn, Uwe, Mier, Walter, Kratochwil, Clemens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451745/ https://www.ncbi.nlm.nih.gov/pubmed/30603987 http://dx.doi.org/10.1007/s00259-018-4220-z

Ejemplares similares

Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals
por: Wüstemann, Till, et al.
Publicado: (2016)

Refined Chelator Spacer Moieties Ameliorate the Pharmacokinetics of PSMA-617
por: dos Santos, José Carlos, et al.
Publicado: (2022)

(18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
por: Giesel, Frederik L., et al.
Publicado: (2016)

Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617
por: Kratochwil, Clemens, et al.
Publicado: (2017)

F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
por: Giesel, Frederik L., et al.
Publicado: (2016)

(68)Ga, (44)Sc and (177)Lu-labeled AAZTA(5)-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues
por: Sinnes, Jean-Philippe, et al.
Publicado: (2020)

Factors Influencing the Therapeutic Efficacy of the PSMA Targeting Radioligand (212)Pb-NG001
por: Stenberg, Vilde Yuli, et al.
Publicado: (2022)

Production, purification, and radiolabeling of the (203)Pb/(212)Pb theranostic pair
por: McNeil, Brooke L., et al.
Publicado: (2021)

In situ Generated (212)Pb-PSMA Ligand in a (224)Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-Positive Cells
por: Stenberg, Vilde Y., et al.
Publicado: (2020)

A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer
por: Eder, Ann-Christin, et al.
Publicado: (2022)

Novel Preclinical and Radiopharmaceutical Aspects of [(68)Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer
por: Eder, Matthias, et al.
Publicado: (2014)

Optimized production, purification, and radiolabeling of the (203)Pb/(212)Pb theranostic pair for nuclear medicine
por: McNeil, Brooke L., et al.
Publicado: (2023)

Evaluation of the PSMA-Binding Ligand (212)Pb-NG001 in Multicellular Tumour Spheroid and Mouse Models of Prostate Cancer
por: Stenberg, Vilde Yuli, et al.
Publicado: (2021)

Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma – Is PSMA-PET-CT a helpful tool in radiation oncology?
por: König, Laila, et al.
Publicado: (2017)

A Theranostic Approach to Imaging and Treating Melanoma with (203)Pb/(212)Pb-Labeled Antibody Targeting Melanin
por: Jiao, Rubin, et al.
Publicado: (2023)

Integration of CT urography improves diagnostic confidence of (68)Ga-PSMA-11 PET/CT in prostate cancer patients
por: Will, Leon, et al.
Publicado: (2017)

Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017)

Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for (203)Pb and (212)Pb-Based Theranostics
por: Li, Mengshi, et al.
Publicado: (2023)

Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
por: Zechmann, Christian M., et al.
Publicado: (2014)

Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer
por: Giesel, F. L., et al.
Publicado: (2016)

Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017)

Radiolabeled PSMA Inhibitors
por: Neels, Oliver C., et al.
Publicado: (2021)

A dimerized urea-based inhibitor of the prostate-specific membrane antigen for (68)Ga-PET imaging of prostate cancer
por: Schäfer, Martin, et al.
Publicado: (2012)

(68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients
por: Sterzing, Florian, et al.
Publicado: (2015)

Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer
por: Stefan A. Koerber, et al.
Publicado: (2020)

PSMA ligands for diagnosis and therapy of prostate cancer
por: Haberkorn, Uwe
Publicado: (2014)

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2018)

(68)Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers
por: Giesel, Frederik L., et al.
Publicado: (2019)

Relative Efficacy of (225)Ac-PSMA-617 and (177)Lu-PSMA-617 in Prostate Cancer Based on Subcellular Dosimetry
por: Lee, Hwan
Publicado: (2022)

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)
por: Kratochwil, Clemens, et al.
Publicado: (2023)

Predicting the Risk of Metastases by PSMA-PET/CT—Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma
por: Koerber, Stefan A., et al.
Publicado: (2021)

2021: the year [(177)Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines?: Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
por: Herrmann, Ken, et al.
Publicado: (2021)

Biodistribution and dosimetry of a single dose of albumin-binding ligand [(177)Lu]Lu-PSMA-ALB-56 in patients with mCRPC
por: Kramer, Vasko, et al.
Publicado: (2020)

PSMA as a target for radiolabelled small molecules
por: Eder, Matthias, et al.
Publicado: (2013)

PSMA-GCK01: A Generator-Based (99m)Tc/(188)Re Theranostic Ligand for the Prostate-Specific Membrane Antigen
por: Cardinale, Jens, et al.
Publicado: (2023)

Biokinetics and dosimetry of (18)F‐PSMA‐1007 in patients with prostate cancer
por: Hvittfeldt, Erland, et al.
Publicado: (2022)

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
por: Ceci, Francesco, et al.
Publicado: (2021)

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2014)

Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation
por: Peters, Steffie M. B., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tcj71um725u7q9u79qfhf7j9dj